LUCKNOW: The Central Drug Research Institute (CDRI) on Tuesday claimed that the clinical trials of antiviral drug Umifenovir in treatment of Covid-19 have been successful, reports Mohita Tewari.
The trial of Umifenovir on 132 Covid patients showed that if proper dose is given twice daily for five days, the drug can effectively reduce viral load in mild or moderate symptomatic and asymptomatic patients by checking multiplication of the virus.
Titled 'Phase III, randomised, double-blind, placebo controlled trial of efficacy, safety and tolerability of Umifenovir vs standard care of therapy in non-severe Covid patients', the clinical trial was conducted at three institutions - King George's Medical University, Ram Manohar Lohia Institute of Medical Sciences and Era's Lucknow Medical College and Hospital.
"Since Umifenovir is a broad spectrum antiviral and is being used as a safe over-the-counter drug for influenza and pneumonia for over 20 years in many countries, the first two trials were not mandatory. CDRI directly went for phase-III trial," CDRI director Tapas Kundu said.
"In a study, double-blind mode improves reliability of results by preventing bias when doctors evaluate patients' outcomes. Results showed patients didn't experience side-effects," he said.
Chief scientist, CDRI, R Ravishankar, said, "Experts said the drug is safe for pregnant women and children."